- Home
- EDIT vs LYEL Comparison
EDIT vs LYEL Comparison
Compare EDIT & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDIT
- LYEL
- Stock Information
- Founded
- EDIT 2013
- LYEL 2018
- Country
- EDIT United States
- LYEL United States
- Employees
- EDIT N/A
- LYEL N/A
- Industry
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- EDIT Health Care
- LYEL Health Care
- Exchange
- EDIT Nasdaq
- LYEL Nasdaq
- Market Cap
- EDIT 269.8M
- LYEL 253.2M
- IPO Year
- EDIT 2016
- LYEL 2021
- Fundamental
- Price
- EDIT $4.01
- LYEL $17.34
- Analyst Decision
- EDIT Buy
- LYEL Hold
- Analyst Count
- EDIT 11
- LYEL 3
- Target Price
- EDIT $4.56
- LYEL $16.67
- AVG Volume (30 Days)
- EDIT 3.3M
- LYEL 66.6K
- Earning Date
- EDIT 11-03-2025
- LYEL 11-06-2025
- Dividend Yield
- EDIT N/A
- LYEL N/A
- EPS Growth
- EDIT N/A
- LYEL N/A
- EPS
- EDIT N/A
- LYEL N/A
- Revenue
- EDIT $38,901,000.00
- LYEL $60,000.00
- Revenue This Year
- EDIT N/A
- LYEL N/A
- Revenue Next Year
- EDIT N/A
- LYEL N/A
- P/E Ratio
- EDIT N/A
- LYEL N/A
- Revenue Growth
- EDIT N/A
- LYEL 11.11
- 52 Week Low
- EDIT $0.91
- LYEL $7.65
- 52 Week High
- EDIT $4.54
- LYEL $30.00
- Technical
- Relative Strength Index (RSI)
- EDIT 63.02
- LYEL 62.87
- Support Level
- EDIT $3.32
- LYEL $15.68
- Resistance Level
- EDIT $4.29
- LYEL $19.44
- Average True Range (ATR)
- EDIT 0.35
- LYEL 1.31
- MACD
- EDIT -0.01
- LYEL -0.01
- Stochastic Oscillator
- EDIT 63.19
- LYEL 70.33
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.